X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aurobindo Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
AUROBINDO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs809365-   
Low Rs504264-   
Sales per share (Unadj.) Rs281.1108.7-  
Earnings per share (Unadj.) Rs41.4-27.4-  
Cash flow per share (Unadj.) Rs50.9-22.7-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.485.3-  
Shares outstanding (eoy) m585.88168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.9 80.7%   
Avg P/E ratio x15.9-11.5 -138.2%  
P/CF ratio (eoy) x12.9-13.9 -93.1%  
Price / Book Value ratio x3.33.7 89.3%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,63053,081 724.6%   
No. of employees `00017.34.3 403.7%   
Total wages/salary Rs m21,3083,331 639.6%   
Avg. sales/employee Rs Th9,500.74,273.4 222.3%   
Avg. wages/employee Rs Th1,229.4776.0 158.4%   
Avg. net profit/employee Rs Th1,397.9-1,076.8 -129.8%   
INCOME DATA
Net Sales Rs m164,66618,346 897.6%  
Other income Rs m1,020128 793.8%   
Total revenues Rs m165,68618,474 896.9%   
Gross profit Rs m37,718-3,179 -1,186.4%  
Depreciation Rs m5,580792 704.7%   
Interest Rs m777497 156.4%   
Profit before tax Rs m32,380-4,339 -746.2%   
Minority Interest Rs m31-12 -259.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183271 3,017.8%   
Profit after tax Rs m24,229-4,623 -524.1%  
Gross profit margin %22.9-17.3 -132.2%  
Effective tax rate %25.3-6.2 -404.4%   
Net profit margin %14.7-25.2 -58.4%  
BALANCE SHEET DATA
Current assets Rs m121,87813,437 907.1%   
Current liabilities Rs m86,8067,560 1,148.2%   
Net working cap to sales %21.332.0 66.5%  
Current ratio x1.41.8 79.0%  
Inventory Days Days130111 117.1%  
Debtors Days Days68124 55.2%  
Net fixed assets Rs m81,0377,832 1,034.7%   
Share capital Rs m58685 687.9%   
"Free" reserves Rs m116,2180-   
Net worth Rs m116,80414,399 811.2%   
Long term debt Rs m4,5125,060 89.2%   
Total assets Rs m211,05227,201 775.9%  
Interest coverage x42.7-7.7 -551.8%   
Debt to equity ratio x00.4 11.0%  
Sales to assets ratio x0.80.7 115.7%   
Return on assets %11.8-15.2 -78.1%  
Return on equity %20.7-32.1 -64.6%  
Return on capital %27.4-19.8 -138.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m46,0270-   
CASH FLOW
From Operations Rs m19,5481,566 1,248.3%  
From Investments Rs m-19,570-481 4,070.1%  
From Financial Activity Rs m8,6424,592 188.2%  
Net Cashflow Rs m8,9225,678 157.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.04 Rs / ZAR

Compare AUROBINDO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: MERCK LTD  ALEMBIC PHARMA  VENUS REMEDIES  DISHMAN PHARMA  IPCA LABS  



Today's Market

Sensex Ends 118 Points Higher; Realty and Banking Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours of trade and ended the day marginally higher.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Nov 15, 2018 03:35 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - NATCO PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS